Successful long-term treatment of philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Myeloproliferative Disorders
  • Philadelphia Chromosome

abstract

  • This is the longest follow-up experience of an HU and AG combination regimen in MPN. The low-dose combination regimen effectively achieved clinical and laboratory response while simultaneously minimizing dose-related adverse reactions, and should be the preferred therapeutic alternative to third-line agents in MPN patients who are resistant or intolerant to monotherapy.

publication date

  • September 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clml.2013.05.015

PubMed ID

  • 24290215

Additional Document Info

start page

  • S300

end page

  • 4

volume

  • 13

number

  • SUPPL. 2